MIRA INFORM REPORT

Report Date :

14.04.2014

IDENTIFICATION DETAILS

Name :	B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT (PERD) CENTRE
Registered Office :	Thaltej - Gandhinagar Highway, Ahmedabad – 380054, Gujarat
Country :	India
Date of Incorporation :	03.07.1988
Capital Investment / Paid-up Capital :	Not Divulged
Legal Form :	Trust
Line of Business :	Service provider of multidisciplinary postgraduate research institute.
No. of Employees :	Not Divulged

RATING & COMMENTS

MIRA’s Rating :

Ba

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory
Payment Behaviour :	Usually correct
Litigation :	Clear
Comments :	The subject is the India’s first multidisciplinary, postgraduate research institute, dedicated to the pursuit of excellence in the pharmaceutical sciences. It is having a satisfactory track record. Trade relations are fair. Business is active. Payments are reported to be usually correct. The institute can be considered normal for any business dealings at usual trade terms and conditions.

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – December 1, 2013

Country Name	Previous Rating (30.09.2013)	Current Rating (01.12.2013)
India	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

INDIAN ECONOMIC OVERVIEW

India’s current account deficit for the fiscal third quarter ended September 2013 narrowed to $4.2 billion or 0.9 % of the gross domestic product from $31.9 billion or 6.5 % of GDP a year earlier, thanks to a pick-up in exports and moderation in gold imports. Manufacturing activity and new orders in India showed their strongest growth in a year in February. The news comes as a relief after data showed Asia’s third largest economy grew by a slower-than-expected 4.7 % annually in the three months through December. The HSBC Manufacturing Purchasing Managers’ Index which gauges the business activity of India’s factories but not its’ utilities, rose to 52.5 in February, its highest in a year from 51.4 in January. Overall new orders for factory goods which rose to a one-year high of 54.9 contributed to the surge. China has emerged as India’s biggest trading partner in the current financial year replacing the United Arab Emirates and pushing it to the third spot. India-China trade has reached $49.5 billion with a 8.7 % share in India’s total trade. The US comes second at $46 billion with 8.1 % share during the first nine months of the current financial year.

The Reserve Bank of India has granted an additional nine months to the public to exchange currency notes printed before 2005 including Rs 500 and Rs 1,000 denominations, pushing the deadline to January 1, 2015. A day before dates for the Lok Sabha polls were announced, the government decided to hike interest rates on fixed deposit schemes offered by post offices up to 0.2 per cent. The new rates will be effective April, 1. The Supreme Court will resume hearing on March, 11 Nokia’s appeal against a ruling over transferring ownership of its local mobile phones plant which is the subject of a tax dispute to Microsoft Corp.

In the last days of the current Government, another scam has surfaced. The defence ministry has ordered a probe into Hindustan Aeronautics Limited’s contracts from Britain’s Rolls-Royce Holdings worth at least $ 1.2 billion. The Central Bureau of Investigation will look into allegations that over $80 million was paid in kickbacks in a deal signed in 2011. India has asked Boeing Co. to find a solution for problems with state-owned Air India’s 787 Dreamliners. The aircraft has experienced a series of malfunctions since its debut in 2011.

RBI DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

INFORMATION DECLINED

MANAGEMENT NON – COOPERATIVE (91-79-27439375)

LOCATIONS

Registered Office :	Thaltej - Gandhinagar Highway, Ahmedabad – 380054, Gujarat, India
Tel. No.:	91-79-27439375/27416409
Fax No.:	91-79-27450449
E-Mail :	perd@perdcentre.com
Website :	http://www.perdcentre.com

MANAGEMENT

Name :

Dr. Jyotikumar Paliwal

Designation :

Director

B. V. PATEL PERD CENTRE TRUST

Name :

Mr. Pankaj R. Patel

Designation :

Secretary

Name :

Mr. Anant R. Thakore

Designation :

Chairman

Members:

• Mr. Sanjay Lalbhai
• Mr. Sudhir Mehta
• Mr. Rajivbhai C. Lalbhai
• Mr. J.B. Mody
• Dr. Dineshbhai S. Patel
• Dr. A.K. Shukla
• Mr. D.B. Gupta
• Mr. Anangbhai A. Lalbhai
• Mr. Shreyansbhai S. Shah
• Dr. Dushyant R. Patel
• Mr. Dilip Shanghvi

SHRI B. V. PATEL EDUCATION TRUST

Name :

Dr. S. P. Adeshara

Designation :

Chairman

Name :

Mr. Girish N. Patel

Designation :

Secretary

Members:

• Mr. Pankaj R. Patel
• Mr. Raojibhai P. Patel
• Mr. R.R. Shah
• Mr. H. G. Koshia

FACULTY

Name :

Dr. Manish Nivsarkar

Designation :

Ph.D., Director

Name :

Dr. Kamala K. Vasu

Designation :

Ph.D., Assistant Director

Name :

Dr. Neeta Shrivastava

Designation :

Ph.D., Assistant Director & Project Director- NIPER Ahmedabad

Name :

Dr. Preeti Desai

Designation :

Ph.D., Scientist-B

Name :

Dr. Anshu Srivastava

Designation :

Ph D., Scientist-B

Name :

Dr. Milee Agarwal

Designation :

Ph.D. Scientist-B

Name :

Dr. Amita Joshi

Designation :

Ph.D. Scientist-B

Name :

Ms. Rajeshwari Rathod

Designation :

M.Sc., Scientist-A

Name :

Mrs. Sweta Patel

Designation :

M. Phil., Research Assistant

Name :

Dr. Rahul Tripathi

Designation :

DPQCQAM, DIPL (Pune), M. Pharm., PhD (IIT-BHU)

Name :

Anirban Samanta

Designation :

Scientist

ADJUNCT FACULTIES

Name :

Dr. Vinod Jairaj

Designation :

Ph.D., Assistant Professor

Name :

Dr. Anita Mahapatra

Designation :

Ph.D., Assistant Professor

Name :

Dr. Sheetal Anandjiwala

Designation :

Ph.D., Assistant Professor

Name :

Dr. Manju Misra

Designation :

Ph.D., Assistant Professor

Name :

Dr. Neelam Chauhan

Designation :

Ph.D., Senior lecturer

Name :

Dr. Mukty Sinha

Designation :

Lecturer

Name :

Dr. Viral Shah

Designation :

Lecturer

Name :

Dr. Bhagvati Saxena

Designation :

Lecturer

ADVISORS

Name :

Dr. V. Sudarsanam

Designation :

Ph.D., Emeritus Scientist

Name :

Prof. Harish Padh

Designation :

Ph.D., Advisor

Name :

Dr. Ruma Baksi

Designation :

Scientific Assistant-B (Dept. of Pharmacology and Toxicology)

Name :

Ms. Rita Rana

Designation :

Scientific Assistant-C (Dept. of Pharmacology and Toxicology)

Name :

Mr. Rakesh Patel

Designation :

Scientific Assistant-A (Dept. of Pharmacology and Toxicology)

Name :

Mr. Nirav Ravat

Designation :

Scientific Assistant-A (Dept. of Pharmacology & Toxicology)

Name :

Mr. Dharmesh Kachhadiya

Designation :

Analytical Chemsitry

Name :

Ms. Sneha Patel

Designation :

Project Fellow

Name :

Mr. Venkatkrishna K

Designation :

Project Fellow

ADMINISTRATIVE STAFF

Name :

Mr. D. R. Trivedi

Designation :

Chief Accounts Officer

Name :

Mr. Jacob Koshy

Designation :

Administrative Officer

Name :

Mr. Georgee Varghese

Designation :

Administrative Officer

Name :

Ms. Bhaviniben

Designation :

Account Officer

Name :

Mr. Vinayak Pangam

Designation :

Technical Officer

Name :

Mr. N. M. Pandya

Designation :

Tech. Assistant (Maintenance)

Name :

Mr. Amrutbhai Makwana

Designation :

Assistant Librarian

Name :

Mr. Dineshbhai Valand

Designation :

Clerk

Name :

Mr. Sunil Jasani

Designation :

Store Assistant

Various Institutional Committees are formed for the smooth functionalization of the centre.

IAEC Committees: LIST OF ANIMAL HOUSE ETHICS Committees MEMBERS

Sr No.	Name of the Members	Category
1.	Dr. Priti Desai (Chairperson)	Biological Scientist
2.	Ms. Rajeshwari Rathod	Scientist from different discipline
3.	Dr. Amita Joshi	Scientist from different discipline
4.	Dr. Ruma Baksi	Veterinarian
5.	Dr. Milee Agarwal (Member secretary)	Scientist In charge of Animal Facility
6.	Dr. Anita Mahapatra	Scientist from outside the institute
7.	Mrs. Simita Banerjee	Non scientific socially aware member
8.	Dr. Ramtej Jayram Verma	CPCSEA Main Nominee
9.	Dr. P.Y. Guru	CPCSEA Link Nominee

IEC Committees: LIST OF INDEPENDENT ETHICS Committees MEMBERS

Sr No.	Name of the IEC Members	Category
1.	Dr. Vipul Turakhia	Chairman
2.	Dr. Mandev B. Patel	Academician
3.	Dr. Biren Nayak	Medical Expert
4.	Dr. (Mrs.) Kusum V. Shah	Academician
5.	Dr. H. J. Trivedi	Academician
6.	Dr. Vishal Y. Mehta	Medical Expert
7.	Mrs. Simita Banerjee	Social Worker
8.	Mr. Ashok Sanghavi	Legal Expert
9.	Dr. Manish Nivsarkar	Member Secretary

IBSC Committees

PERD Centre is actively involved in various recombinant (rDNA) research work. We have our Institutional Biosafety Committees (IBSC) comprising of a Department of Biotechnology (DBT) Nominee, and other external as well internal experts, who review all recombinant research carried out at our centre. The Committees assures that all the rDNA work is carried out according to the DBT guidelines for Biosafety.

Sr No.	Name of the IBSC Members	Category
1.	Dr. Manish Nivsarkar	Chairman
2.	Dr. Rasheeda Begum	DBT Nominee
3.	Dr. D. D. Singh	External Expert
4.	Dr. Prabhudas Patel	External Expert
5.	Dr. Vipul Turakhia	Biosafty Officer
6.	Prof. Harish Padh	Member
7.	Dr. Neeta Shrivastava	Member
8.	Dr. Neelam Chauhan	Member Secretary

Purchase Committees

Sr No.	Name of the Members	Category
1.	Dr. Kamala K. Vasu	Asst. Director
2.	Dr. Amita Joshi	Scientist-B
3.	Mrs. Sweta A. Patel	Research Assistant
4.	Mr. Jacob Koshy	Administrative Officer

Fire & Safety Committees

Sr No.	Name of the Members
1.	Dr. Kamala K. Vasu

Women Grievance Cell

Sr No.	Name of the Members
1.	Dr. Kamala Vasu- Chair person
2.	Dr. Sheetal Aandjiwala
3.	Dr. Millee Agarwal
4.	Ms. Bhavini Ganatra

ALUMNI

Dr. Sonia Guha Post Doctoral Fellow, University of Pennsylvania, Philadelphia	Dr. Bhavesh Vats Sr. Research Investigator, Syngene International Limited Email: bhaveshvats@gmail.com
Dr. Nidhi Vats Email : nidhineekhra@yahoo.com	Dr. Neelam Chauhan Senior Lecturer, NIPER – Ahmedabad Email: neelam013@yahoo.co.in
Dr. Preeti Desai Scientist-B, B. V. Patel PERD Centre, Ahmedabad Email : preetindesai@yahoo.co.in	Dr. Milee Agarwal Scientist - B Department of Pharmacology and Toxicology B. V. Patel PERD Centre- Ahmedabad Email: milee.agarwal@yahoo.com
Dr. Dipali Dhawan Post Doctorate Fellow, Department of Life Sciences, Ahmedabad University, Ahmedabad, Gujarat. Email : dipali.dhawan@gmail.com	Dr. Parendu D. Rathod Group Leader, Process Chemistry, Ranbaxy Laboratories Limited Gurgaon, India. Email: parendu.rathod@ranbaxy.com
Dr. Ajay D. Pillai Group leader, Quest Life Sciences, Surat, India. Email : hmtlion@gmail.com	Dr. Rajan S. Giri R&D Scientist Cobrek Pharmaceuticals Inc, Chicago, USA Email: rajan007giri@gmail.com
Dr. Gajanan S. Inamdar Group Leader, Drug Discovery, Sphaera Pharmaceuticals (Private) Limited Manesar, Haryana, India. Email : gajanasinamdar@gmail.com	Dr. Swapnil G. Yerande Group Leader, Acoris Pharmaceuticals (Private) Limited Pune, India. Email: swapnilyerande@rediffmail.com
Dr. Jitendra C. Kaila Chief Scientist, Synzeal Research (Private) Limited Ahmedabad, India Email : jitendrakailac@gmail.com	Dr. Amit N. Pandya Post doctoral Fellow, Creighton University, Nebraska, Omaha, USA Email: amitnpandya@gmail.com
Dr. Hitesh B. Jalani Post-Doctoral Fellow, College of Pharmacy / Institute of Drug Research and Development, Department of Medicinal Chemistry, Chungnam National University (CNU) Daejeon - 305764 South Korea. Email: hbjalani@gmail.com	Dr. Arshi B. Baraiya Research Scientist, Synzeal Research (Private) Limited Ahmedabad, India Email: abbaraiya@gmail.com
Dr. Chintan Vayeda Group Leader, Dr. Reddy’s Laboratory, Hyderabad, India	Dr. Swati V. Pund Assistant Professor, Sinhgad Institute of Pharmacy, Narhe, Pune Email: swatipund@gmail.com
Dr. Aryamitra Banerjee (Pharmacology and Toxicology) Study Director Toxicology Research Laboratory and Research Assistant Professor Department of Pharmacology University of Illinois at Chicago 808 South Wood Street, Room 1308 Chicago, IL 60612 Email : aryamitrab@yahoo.com	Dr. Bhupendra Chauhan Email: bhupendra_chauhan@rediffmail.com Dr. Anshu Srivastava Scientist-B, Dept. of Pharmacognosy and Phytochemistry, B.V. Patel PERD Centre, Ahmedabad, India. Email : anshusrivastava@gmail.com
Dr. Amita K. Joshi Scientist-B, Department of Pharmaceutics, B V Patel PERD Centre, Ahmedabad Email : amitagarg4@gmail.com	Mr. Arpan Chudasama Post doctoral Fellow, Dept. of Pharmaceutics, B.V. Patel PERD Centre Email: arpanchudasama@rediffmail.com
Mr. Vineet V. Patel Research Fellow, Emcure Pharmaceuticals Limited, Pune. Email : patelvineetv@yahoo.co.in	Dr. Hitesh Doshi Indeus, Life Sciences Private Limited Mumbai Email: hitesh.doshi@indeus.in, hiteshdoshi@hotmail.com
Dr. Shanthakumar T. R. Research Fellow, SIGA Technologies. Orissa. Email : shanthak22@yahoo.com	Dr. Ajaykumar Handa Alembic Research Centre. Vadodara Email: ajayhanda123@rediffmail.com
Dr. Chetan Doshi Apotex Inc. Canada Email : cdoshi@apotex.com	Dr. M. N. Ravishankara Manager (R and D), Analytical Development Department (ADD), SPARC, Baroda Email: mnravisha@gmail.com
Dr. V. Prashanth Kumar Manager, CMO, Greater New York City Area Email: vprashanthkumar@yahoo.com	Dr. Milind Bagul Manager, Bioanalytical Department, Raptim Research Limited., Navi Mumbai Email: msbagul@yahoo.com
Dr. Niranjan Kanaki Assistant Professor, KBIPER, Gandhinagar. Email: niranjanskanaki@yahoo.co.in	Dr. H. Srinivasa Research Scientist, Glenmark Research Centre, Glenmark Pharmaceuticals Limited., Navi Mumbai Email: sriniuh@gmail.com
Dr. Yogesh Biradar Research Scientist I, Orchid Research Laboratories Limited., Chennai Email: biradar_yogesh@rediffmail.com	Dr. Astha Varma astha.rajneesh@gmail.com
Dr. Rahul Prakash Joshi Senior Research Associate II Piramal Discovery Solutions, Shirish Research Campus, 18, PHARMEZ- Pharmaceutical Special Economic Zone (SEZ) Sarkhej- Bavla Road, Sanand, Ahmedabad- 382213, Email: rahuljoshi.pharm@gmail.com	Dr. Arpan Chudasama Emcure Pharma, Ahmedabad
Dr. Rahul Joshi Senior Research Associate Analytical – II Piramal Discovery Solutions, Shirish Research Campus, 18, PHARMEZ- SEZ Sarkhej-Bavla Road, Matoda, Sanand, Ahmedabad - 382213	Dr. Suhani Almal Post Doctorate Fellow B. V. Patel PERD Centre, Ahmedabad Email: almalsuhani@gmail.com

LOCAL AGENCY FURTHER INFORMATION

Sr. No.	Check List by Info Agents	Available in Report (Yes / No)
1]	Year of Establishment	Yes
2]	Locality of the firm	Yes
3]	Constitutions of the firm	Yes
4]	Premises details	No
5]	Type of Business	Yes
6]	Line of Business	Yes
7]	Promoter's background	Yes
8]	No. of employees	No
9]	Name of person contacted	No
10]	Designation of contact person	No
11]	Turnover of firm for last three years	No
12]	Profitability for last three years	No
13]	Reasons for variation <> 20%	--
14]	Estimation for coming financial year	No
15]	Capital in the business	No
16]	Details of sister concerns	No
17]	Major suppliers	No
18]	Major customers	No
19]	Payments terms	No
20]	Export / Import details (if applicable)	No
21]	Market information	--
22]	Litigations that the firm / promoter involved in	--
23]	Banking Details	No
24]	Banking facility details	No
25]	Conduct of the banking account	--
26]	Buyer visit details	--
27]	Financials, if provided	No
28]	Incorporation details, if applicable	No
29]	Last accounts filed at ROC	No
30]	Major Shareholders, if available	No
31]	Date of Birth of Proprietor/Partner/Director, if available	No
32]	PAN of Proprietor/Partner/Director, if available	No
33]	Voter ID No of Proprietor/Partner/Director, if available	No
34]	External Agency Rating, if available	No

AS PER WEBSITE DETAILS

Imagination, innovations and finally inventions, have marked the progress of man at each step of evolution.

In October 1990 the B. V. Patel Education Trust in conjuncture with the Indian Pharmaceutical Association established B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, in the memory of late Mr. B. V. Patel, the first Drug Controller of Gujarat.

Started with the express aim of providing the Pharmaceutical industry and academia the opportunity and resources to undertake the latest in research and development, PERD Centre is India's first multidisciplinary, postgraduate research institute, promoting advanced research, services and training in the field of pharmaceutical sciences.

A non-profit organization, PERD Centre acts as a supportive partner to the pharmaceutical industry and academia, providing the facilities and resources to undertake the latest in research and development.

As an industry-academia-government collaboration, PERD offers

• Well equipped laboratories and research facilities
• Expert services of scientific and technical personnel
• A well stocked, spacious library
• Regular education, training and developmental activities

TRUSTEES

The B. V. Patel PERD Centre Trust was established on 3rd July, 1988 by Shri B. V. Patel Education Trust which consists of a Chairman, Secretary and nine members from many well known scientists/industrialists. The present Chairman and Secretary of the Trust are Shri Anant R. Thakore, Managing Director, Avik Pharmaceuticals, Mumbai and Shri Pankaj R. Patel, Managing Director, Zydus Cadila Healthcare, Ahmedabad, respectively. The activities of the centre are overseen by the Board of Trustees, with the Chairman of the Trust as the Chairman of the Centre.

RESEARCH

DEPARTMENT OF ANALYTICAL

• Physico-chemical characterization of new chemical entities
• Forced degradation (stress testing) and stability kinetics studies
• Validated analytical method development including stability-indicating assays
• Impurity profiling of drug substances
• Preparation of degradation product standards

DEPARTMENT OF BIOSTATISTICS

Statistical research in bioequivalence and bioavailability studies, clinical trials. Statistical analysis on Gene Expression data and other pharmaceutical field.

DEPARTMENT OF CELL AND MOLECULAR BIOLOGY

The Cell and Molecular Biology Department at B.V. Patel PERD Centre is involved in various facets of basic and applied research. The current research pursuits include population based genomic analyses and multiple molecular therapeutic approaches for various diseases.

Cell Biology

The Department of cell biology focus on: Stem cells, Cancer and Neurobiology.

Stem Cells:

Non-viral methods for inducing pluripotency

Human induced pluripotent stem cells (hiPSCs) derived from patient samples have tremendous potential for innovative approaches to disease pathology investigation and regenerative medicine. This project involves the use of a ‘minicircle’ DNA vector and recombinant reprogramming proteins for generation of iPSCs.

Cancer stem cells and epithelial to mesenchymal transition (EMT)

The cellular processes enabled by EMT during cancer metastasis appear to be analogous to the process of tissue reconstruction by adult stem cells. However, this process is not well understood in cancer and this proposal will investigate the cell types and signals required for EMT and the regulation of the rare and often drug resistant population of cancer stem cells (CSCs).

Cancer:

Alleviating cancer chemoresistance using NF-κB inhibitors

The project evaluates the role of NF-κB inhibitors as chemosensitizers against acquired and innate cancer chemoresistance.

Evaluation of interplay between STAT3 and Survivin in mediating cancer chemoresistance

Activated Signal transducer and activator of transcription 3 (STAT3) is involved not only in cell transformation but also in tumor escape to genotoxic treatments. Furthermore, survivin which is over expressed in almost all types of human malignancies, functions as a key factor in chemoresistance. The aim of present study is to establish cancer cell line models to study the effect of activated STAT3/survivin in mediating cancer chemoresistance.

Drug Delivery and Drug targeting in to cancer cells using Therapeutic Nanoparticles

This project involves, design and synthesis of therapeutic iron oxide nanoparticle for targeted drug delivery in cancer. This will help in decreasing the side effects of chemotherapy by lowering the dose of chemotherapeutic.

Neurobiology:

Stimulation of neuronal precursors using natural products in combination with neurotrophic factors

The main aim of the project is to stimulate the neuronal precursors using some selected plant extracts in combination with neurotrophic factors.

Effect of Mycobacterial lipid and Freund’s adjuvant on permeability of blood brain barrier (BBB)

In this project, they aim to elucidate the effect of various Mycobacterial lipids and CFA on the in vitro model of BBB.

Neuroprotection in stroke

Stroke and seizures are the gravest neurological problems worldwide. The potential of inhibiting the neuro-inflammatory mediators to inhibit the stroke induced seizures and subsequent epilepsy has not yet been fully exploited and is the main aim of their research.

Molecular Biology

Pharmacogenomics and Biotherapeutics are their main focus areas

Pharmacogenomics:

Genetic Variations in Indian population

Genetic variations in terms of single nucleotide polymorphism (SNPs) and copy number variations (CNVs) and its involvement in disease susceptibility and drug response is being studied in Indian population. They are focusing mainly on cancer (breast and head and neck cancer), diabetes, psoriasis, asthma, HIV-1/AIDS, malaria and tuberculosis diseases.

Biotherapeutics:

Development of Novel vaccine against Shigella dysenteriae type-1 (SD-1)

Shigellosis is a grave diarrheal disease responsible to infant mortality in developing countries like India and not a single approved vaccine is available. Their approach for the development of vaccine for SD1 is use of food grade bacteria Lactocoocus lactis to deliver the cell surface antigens of SD1 to the lumen of intestine to generate the protective antibody against it.

Use of molecular and chemical approaches for the enhancement of Therapeutic protein expression in CHO cells.

Recombinant therapeutic proteins produced in mammalian cells represent a major class of biopharmaceuticals. In this project they aim to increase the expression of therapeutic proteins by using Molecular and chemical approaches.

DEPARTMENT OF MEDICINAL CHEMISTRY

The focus of their research work is based on the use of latest methods of organic syntheses in combination with information accumulated from the methods of molecular modeling (especially, small molecules) to design and synthesize small molecules that can be used to gain a better understanding of the function of specific molecular targets.

Design of their molecules are based on various approaches such as Fragment-based design, Chemical Lead based design, Scaffold hopping approach and structure based drug design of novel chemical entities.

Based on the above designing approaches, the designed molecules are synthesized by novel and latest organic

synthesis methods like:

- Multi-component reactions (MCRs),

- Solid phase synthesis for both small molecules and small peptides

- Modification of small natural product molecules

Screening of these novel molecules for their therapeutic potency for treating human diseases like:

- Cancer

- Asthma

- Radioprotection

- Alzheimer’s disease and

- Tuberculosis

The current focus of the laboratory is the development of newer ligands, hits and NCEs in the form of small heterocycles and peptides as novel inhibitors of NF-kB, AP-1, and VEGF receptors with potential application in cancer, radioprotection.

Currently one of their molecules is undergoing preclinical trials for the advanced prostate cancer and breast cancer at the Louisiana State University, Shreveport, USA.

DEPARTMENT OF MICROBIOLOGY

Their expertise lies in anti-microbial testing on broad range of bacterial and fungal cultures, which are according to the pharmacopeial guidelines. They mainly carry out anti-microbial activities of their in-house synthesized new chemical entities (NCEs) and herbal drugs along with the microbial load test, etc. They are also actively involved in anti-mycobacterial activity of NCEs along with the determination of cytotoxicity on Mycobacteruim species.

DEPARTMENT OF PHARMACOGNOSY AND PHYTOCHEMISTRY

Natural products

Authentication of herbal drugs using Integrative Taxonomy (Classical, Chemo- and Geno-).

Developing pharmacopoeial methods for standardization of herbal drugs, herbal extracts and polyherbal formulations. The work includes developing methods of standardization for pharmacognostic and phytochemical evaluation of herbal drugs and formulations. The work also involves isolation and characterization of active principles/marker compounds and establishing methods for the quantification of marker compounds using HPTLC, HPLC or GLC.

Isolation of biomarkers using various techniques viz., solvent extraction, column chromatography, preparative HPLC, preparative TLC.

Establishing extensive QA/QC parameters, carrying out stability studies of herbal drugs and formulations.

Developing SOPs for the preparation of polyherbal Ayurvedic formulations, establishing pharmacopoeial standards and carrying out shelf-life studies.

Evaluation of plant extracts for radioprotective, neuroregenerative, anticancer, anti-malarial, anti-inflammatory, anti-diabetic, anti-hypertensive, anti-allergic, antimicrobial, hepatoprotective, cytotoxic and antioxidant activities and bioactivity guided fractionation leading to the isolation of active principles from herbal extracts.

Pharmacokinetic and Bioavailability Studies of selected plants of Indian Systems of Medicine.

Formulating Natural Products into conventional pharmaceutical dosage forms viz. Tablets, capsules, ointments, gels, in-situ gels, hydrogels, liposomes.

Natural Product Chemistry

Synthesis and development of New Chemical Entities (NCEs) as leads.

Screening of natural scaffolds and synthetic analogues against M. bovis and resistant strains of M. tuberculosis for discovery of new anti-TB agents. They have started working on target based screening of the analogues.

Development of natural scaffolds and their semi-synthetic derivatives as emergency contraceptives by studying the anti-implantation activity and mechanism of action by inhibiting enzymes or pathways.

Plant Biotechnology

Design and development of protocols for tissue culture of medicinal plants – Many protocols have been developed for micropropagation, shoot regeneration, root regeneration, callus culture and cell suspension culture of various medicinal plants like Horarrhena antidysenterica, Clerodendrum inerme, Bacopa monnieri, Cassia senna, Adhatoda vasica, Boerhaavia diffusa, Terminalia arjuna, Balanitis roxburghii, Catharanthus roseus, Nicotiana tabacum, etc. The protocols have also been established for production of secondary metabolites in tissue cultures.

Production of therapeutic proteins in plants – Protocols have been standardized for genetic transformation of various plants for production of therapeutic proteins, plantibodies, reporter proteins, etc.

Development of molecular markers for authentication of medicinal plants – Development of DNA fingerprint profile of the plants have been standardized for authentication of medicinal plants like Terminalia arjuna, Saraca asoca, Phyllanthus amarus, etc. This technique will help in identification and authentication of medicinally important plant species at commercial level and preventing adulteration of crude drug preparations. The technique can also be used to develop SCAR markers and ESTs for identification and authentication of medicinally important tree species. The technique has also been exploited for marker-assisted selection for high-yielding varieties of the plant based on the concentration of their therapeutically active marker compound.

RNA interference – The technique has also been used in plant systems for silencing of desired target gene. This has been used in metabolic engineering for trait improvement.

Animal Biotechnology

Cancer therapeutics – RNA interference has been used in vitro and in vivo to downregulate overexpressing oncogenes mediating cancer angiogenesis, apoptosis and metastasis. The proof of principle can open new vistas for cancer therapy.

DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY

• Identification of Toxicity Biomarkers
• Diabetic Complications
• shRNA Delivery
• Pharmacokinetic Studies of NCEs, NDDS and Herbal drugs
• Reproductive Physiology
• Cerebral Ischemia
• In Vitro ADME Studies
• Multiple Sclerosis

DEPARTMENT OF PHARMACEUTICS

Currently, the department is involved in the development of novel drug delivery systems (DDS) for fixed dose combination of anti-tubercular drugs. This project is funded by DBT, Govt. of India. The department is also engaged in the development of osmotic pumps of psychiatric drugs and Self-emulsifying drug delivery system for anti-retroviral and antifungal drugs, transdermal therapeutic systems for contraceptives, MAO inhibitors and migraine.

Various projects involving novel therapeutic systems like, Solid-lipid nanoparticles, Orodispersible films, Pulsatile DDS, Colon targeted DDS, Microparticle, Micro- emulsions etc, along with four industry sponsored projects are currently underway.

AREA OF EXPERTISE

• DRUG DELIVERY SYSTEMS
• Pulsatile drug delivery systems
• Gastroretentive drug delivery systems
• Controlled release formulations
• Floating bioadhesive
• Colon targeted drug delivery systems
• Osmotic drug delivery systems
• NANOCARRIERS
• Solid lipid nanoparticles
• Liposomes
• Niosomes
• Microemulsions
• Self Emulsifying Drug Delivery Systems
• Transdermal Drug Delivery Systems
• Mouth dissolving films

INDUSTRIAL SERVICES

DEPARTMENT OF ANALYTICAL

The department is involved in various activities, including active involvement in industrial research projects. The key areas of research are:

• The department is undertaking BA/BE studies of pharmaceuticals
• Method development and validation on turn-key basis
• Annual Instruments training workshops / Individual training on above instruments

DEPARTMENT OF BIOSTATISTICS

Consultancy

Design, Statistical Analysis and Documentation of BA BE study, Clinical Trials, Data Management

DEPARTMENT OF CELLULAR MOLECULAR BIOLOGY

• Design and development of expression vector for bacterial, mammalian and plant systems
• In Vitro cytotoxicity assay for various pharmaceutical drugs
• Custom based pharmacogenomic testing for different genes and drug metabolizing enzymes starting from designing of the reaction to actually genotyping the samples

DEPARTMENT OF MEDICINAL CHEMISTRY

Chemistry Services to Industries

• Custom synthesis form mg to multigram scale for various compound libraries
• Route scouting and product development for (SMEs)
• Developmental work of drugs/dyes/fine chemicals intermediates
• Impurity identification, characterization and synthesis of various APIs
• API synthesis work
• Synthesis of building blocks to assist drug discovery process
• Intermediate synthesis
• Process development of APIs
• Synthesis of drug metabolites
• Sybyl 6.9 (Tripos, Inc. USA) work station
• Generation of new leads using 3D QSAR
• 3D-QSAR and Molecular Docking facility is available with the department

Analytical Chemistry related Services to Industries

• Analysis of New Chemical Entities and purification using HPLC
• Stress degradation studies of APIs
• Isolation and structural elucidation of degraded products
• Identification and characterization of process related impurities present in APIs
• Stress degradation studies of important natural products
• Identification and characterization of process related unknown impurities
• Analytical method development, validation and estimation of APIs

DEPARTMENT OF MICROBIOLOGY

They provide various industrial services according to the pharmacopeial guidelines as follow:

• Anti-bacterial activity
• Anti-fungal activity
• Anti-mycobacterial activity
• Microbial load test
• Microbial limit test
• LAL testing
• Micro dilution assay

DEPARTMENT OF PHARMACOGNOSY AND PHYTOCHEMISTRY

• Identification and Authentication of Plant/Plant Material
• Macroscopic and microscopic examination of herbal drugs and polyherbal formulations
• Qualitative and quantitaive analysis of steroids from herbal drugs and polyherbal formulations
• Development of Quantitative standards, viz., Extractive values, Ash values, Fixed oil content, Loss on Drying
• Development of Phytochemical Profiles (Fingerprint) using HPTLC,/HPLC/GC/GLC depending upon the nature of the sample
• Isolation of Marker compounds using various techniques
• Estimation/Quantification of Active /Marker compounds using HPTLC, HPLC, GLC, GC
• Microbial Load Testing
• Bioassay guided isolation of active compounds as antifungal leads
• Authentication of herbal raw material using DNA fingerprint profile (molecular markers)
• Development of tissue cultures of medicinally and economically important plants and consultation

DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY

• Bioequivalence and Bioavailability Studies
• Pharmacological Studies
• Toxicity Studies
• Pre-clinical Pharmacokinetic Studies

DEPARTMENT OF PHARMACEUTICS

• All Facility for solid oral dosage form development starting from dispensing, sifting, mixing granulation, drying, compression to coating are available
• Similarly facility for permeation studies especially for patches, Nano particulate formulation development and estimation, analytical method development, validation, and stability are also provided to industry
• Details of all the equipments and machinery are given in the facility section which can be given to small scale industries for their work

DIRECTOR

The B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre has been established in 1989 by the Gujarat Branch of the Indian Pharmaceutical Association with the help of Indian pharmaceutical companies and the Government of Gujarat, in the memory of late Shri. B. V. Patel, who was the first Drugs Controller of Gujarat and truly considered father of drug legislation in India.

This grant-in-aid institute of Government of Gujarat, which was inaugurated in 1990 by Professor M. G. K. Menon.

The institute is the first leading multidisciplinary institute in the field of pharmaceutical education and research in India and has good infrastructure facilities such as well equipped laboratories, auditorium, seminar room, library, etc., with learned staff members.

The Centre is recognised as a SIRO by DSIR and its Ph.D. programme is recognized by All India Institute of Technical Education (AICTE), Bhavnagar University, Nirma University, Sardar Patel University and BITS Pilani. More than thirty students have completed their Ph.D. at the Centre and currently about 30 students are pursuing their Ph.D. programe in various disciplines. The Centre has been undertaking research projects from Government funding agencies like Indian Systems of Medicine (ISM), ICMR, DST, CSIR, Department of Biotechnology (DBT), GUJCOST, etc., and providing some of the quality services to the industry in the areas of Bioequivalence, Toxicity studies, Biotechnology, Pharmacology and Phytochemistry. The research work at PERD Centre has resulted in the form of peer reviewed publications in reputed international journals. Several national and international patents have been filed from various departments of PERD Centre. In addition to this, the institute regularly conducts need based workshops and seminars for academicians and technocrats from the pharmaceutical industry and so far conducted 91 such programmes, and 7 international symposia.

During last decade, PERD has contributed significantly towards advancing pharmaceutical education and research in their country. It has been developed on the public-private partnership and offers excellent interface for academic-industry-government interactions.

In the year 2007, Ministry of Chemicals and Fertilizer chose PERD as mentor institute for setting up NIPER in Ahmedabad. While the 60-acre campus for NIPER Ahmedabad is poised for construction in Gandhinagar, NIPER’s M.S.Pharm. program is running at PERD for past 5 years. 

PERD has recently added new facilities like Animal Cell Tissue Culture, Stem Cell Culture and Incubator facility with the help of funds from government funding agencies.

I welcome you to visit their site and learn more about the activities of the Centre.

CMT REPORT (Corruption, Money Laundering & Terrorism]

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

1] INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

2] Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

3] Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

4] Record on Financial Crime :

Charges or conviction registered against subject: None

5] Records on Violation of Anti-Corruption Laws :

Charges or investigation registered against subject: None

6] Records on Int’l Anti-Money Laundering Laws/Standards :

Charges or investigation registered against subject: None

7] Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

8] Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

9] Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

10] Press Report :

No press reports / filings exists on the subject.

CORPORATE GOVERNANCE

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

CONTRAVENTION

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.60.27
UK Pound	1	Rs.101.10
Euro	1	Rs.83.74

INFORMATION DETAILS

Information Gathered by :	PRT
Analysis Done by :	RAS
Report Prepared by :	KVT

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
--	NB	New Business	--

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.